Sentences with phrase «lung cancer survival in»

Comorbid conditions can affect lung cancer survival in many ways, including complicating diagnostic evaluation, leading to less accurate disease staging, he added.

Not exact matches

Merck's cancer immunotherapy Keytruda is one of the pharma giant's rising stars, especially in the wake of evidence that the therapy had a survival benefit over standard chemotherapy in advanced lung cancer patients.

Related Articles: Merck's Keytruda held back by docs who don't want to wait for diagnostics Bristol's Opdivo - Yervoy combo ups response rates in first - line lung cancer patients Roche's Tecentriq bursts onto immuno - oncology scene, with Merck and BMS in its sights Bristol - Myers» new Opdivo ad touts biomarker advantage over Merck's Keytruda Merck's Keytruda lines up its survival data for stepped - up battle with BMS» Opdivo

April 16 Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly - diagnosed patients with advanced non-small cell lung cancer in a highly - anticipated study that appears to cement the company's lead in the most lucrative oncology market.

The biotech specialist said that its updated phase 2 data in a study of its poziotinib candidate treatment for non-small cell lung cancer resulted in a preliminary confirmed objective response rate and potential progression - free survival benefit in patients with the EGFR Exon 20 Mutant form of the disease.

If hypofractionated radiation with curative intent can reduce the treatment time for lung cancer patients by half with no greater toxicity, and with equivalent — if not better — tumor control and survival outcomes, this research could result in a change in the paradigm of how a large subset of locally advanced NSCLC patients are treated.»

Unfortunately, the treatment had little effect on the survival of the terminally ill lung cancer patients in the first trial.

One, in which Dr. Weiss was the senior author, highlighted the extended survival of metastatic small cell lung cancer (SCLC) patients who received statins.

According to the National Cancer Institute, the 5 - year survival of all patients diagnosed with lung cancer in the United States is approximatelyCancer Institute, the 5 - year survival of all patients diagnosed with lung cancer in the United States is approximatelycancer in the United States is approximately 17 %.

In examining the STS - CMS linked data, researchers found that the median survival following lung cancer surgery for pathologic Stage I (early stage) was 6.7 years, almost 2 years longer than the benchmark 5 - year survival rate.

In addition, the study showed that the 5 - year survival rate for selected older patients with advanced lung cancer who were treated with surgical therapy was 29.9 % for Stage III and 26.7 % for Stage IV.

Key findings in this study show that 5 - year survival for older lung cancer surgery patients is favorable; surgeons will be able to better individualize care for older lung cancer patients based on newly and uniquely linked data, and the prevalence of lung cancer is expected to increase as the population continues to age.

«This greater than expected survival in older patients selected for operative therapy is noteworthy,» said Dr. Fernandez, «especially considering that the prevalence of lung cancer is expected to increase as the population continues to grow older and more people survive into old age.»

Among patients with non-small cell lung cancer (NSCLC) fueled by ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in the number of circulating tumor cells (CTCs) harboring increased copies of the ALK gene over the first two months of treatment was associated with increased progression - free survival.

Lung cancer causes the most cancer - related deaths in the United States, and researchers are searching for new cellular targets to increase survival rates.

Progression - free survival in the trial escalated from 3.5 months to 9.7 months with the addition of radiation therapy delivered to all the metastatic sites of lung cancer as well as the primary disease site.

Few existing treatments offer durable survival benefits for patients whose NSCLC has spread past the lungs, due in part to the aggressive nature of lung cancer and its propensity to progress, even following treatment.

Among patients with advanced non-small cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement in survival without progression of the cancer, but not with overall survival, according to a study in the April 9 issue of JAMA.

By identifying the cause of this metastasis — which often happens quickly in lung cancer and results in a bleak survival rate — Salk scientists are able to explain why some tumors are more prone to spreading than others.

Ceritinib provides longer progression - free survival than chemotherapy in crizotinib - pre-treated patients with non-small-cell lung cancer harbouring an ALK rearrangement, according to results of the phase III ASCEND - 5 study presented at the ESMO 2016 Congress in Copenhagen.

«We now know much more about metabolic reprogramming of cancerous tissues in human patients, particularly that the activation of pyruvate carboxylase is important to lung cancer cell growth and survival,» said Fan, UK professor of toxicology and faculty member of the Markey Cancer Center and CESB at the University of Kencancer cell growth and survival,» said Fan, UK professor of toxicology and faculty member of the Markey Cancer Center and CESB at the University of KenCancer Center and CESB at the University of Kentucky.

«Rare mutation may extend survival in lung cancer patients with brain metastases.»

While lung cancer is the leading cause of cancer death and the second most commonly diagnosed cancer in both men and women, a low survival rate makes it the number eight cancer site represented among survivors.

In the last two decades lung cancer therapy has improved, but the overall 5 - year survival rate is still quite low at 17 %.

The cells exhibited many functions associated with tumor progression; their presence within mouse tumors substantially accelerated cancer growth, and in human lung tumors, a SiglecFhigh neutrophil signature was associated with poor patient survival.

«Programs that provide treatment for lung cancer also must measure their performance actively and carefully in order to improve the quality of care and improve patients» chances of survival.»

Such a positive survival rate is encouraging considering that historically conventional RT resulted in poor tumor control for patients with inoperable lung cancer.

With the advancement of surgical and radiation therapy strategies for stage 1 non-small-cell lung cancer (NSCLC), more patients are being treated, resulting in higher survival rates, according to a study published online today in The Annals of Thoracic Surgery.

The immunotherapy drug pembrolizumab, when combined with chemotherapy, doubles survival in patients with non-squamous non-small cell lung cancer (NSNSCLC) lacking genetic changes in the EGFR or ALK genes, when compared to...

They found that early phenformin treatment causes increased survival and slower tumor progression in tumors lacking LKB1, but had no significant benefit for tumors with alterations in other lung cancer genes.

Long - term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole - brain radiotherapy and thoracic chemoradiation.

Now, in a new study in the journal Cancer Cell, Shaw and a team of scientists at the Salk Institute for Biological Studies found that phenformin, a derivative of the widely - used diabetes drug metformin, decreased the size of lung tumors in mice and increased the animals» survival.

A randomized, phase II trial showed improved progression - free survival in small - cell lung cancer with maintenance sunitinib vs placebo following standard chemotherapy, according to results presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

Injections of iPSC - EPCs did not however have significant effect on tumor growth or on overall survival, but transducing cells with a baculovirus expressing CD40L, a member of the TNF gene family which can induce apoptosis [6, 7], and injection into the breast cancer lung metastasis, increased levels of pro-apoptotic cytokines in lung tissues, indicating the induction of apoptosis by CD40L carried by the EPCs (See figure).

He concluded that the improvement in progression - free survival and potential for overall survival benefit should lead to a phase III trial of this therapy option in small - cell lung cancer.

The dual - drug therapy — with analogs already in use for other diseases — doubled the survival rate of mice with lung cancer and halted cancer in pancreatic cells.

DENVER — Leptomeningeal metastases (LM), a devastating complication and predictor of poor survival in lung cancer patients, was found to be more prevalent in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations.

In some cases, surgeons have successfully treated such limited cancer spread, producing long - term survival by removing the primary cancer and one or two distant tumors, off - shoots of the original cancer — usually in the lung or liveIn some cases, surgeons have successfully treated such limited cancer spread, producing long - term survival by removing the primary cancer and one or two distant tumors, off - shoots of the original cancer — usually in the lung or livein the lung or liver.

The work that garnered the honor, «An analysis of the risk and benefit of neoadjuvant chemotherapy among patients undergoing surgery for non-small cell lung cancer,» examined data from more than 134,000 patients in the National Cancer Database to assess the impact of neoadjuvant therapy on perioperative outcomes, as well as long - term surcancer,» examined data from more than 134,000 patients in the National Cancer Database to assess the impact of neoadjuvant therapy on perioperative outcomes, as well as long - term surCancer Database to assess the impact of neoadjuvant therapy on perioperative outcomes, as well as long - term survival.

Whitehead Institute researchers have found that an ancient, highly conserved cell survival factor drives expression of a specific set of genes that is strongly associated with metastasis and death in patients with breast, colon, and lung cancers.

Life table modelling on the basis of these data estimated 33 % five year survival in 65 year old patients with early stage non-small cell lung cancer who continued to smoke compared with 70 % in those who quit smoking.

Studies on the effects of GHRH antagonists on prostate and lung cancers demonstrated their ability to modulate signaling pathways involved in cellular proliferation, survival, metastasis, and apoptosis.

Pharmaceutical giant Merck's flagship immunotherapy drug that was just approved by the United States Food and Drug Administration (FDA) shows promise in the overall survival rate among patients suffering from one of the deadliest type of cancer that affects the lungs.

Saturday, Oct. 21, 9:15 - 9:30 a.m., Room 220B, South Building Platform Presentation: Epigenetic modifications of innate immunity genes impact early - stage non-small cell lung cancer survival: An integrative analysis of epigenome and transcriptome in Caucasian population R. Zhang, Harvard T.H. Chan School of Public Health, et al

Comparison of smoking and non-smoking lung cancer patients finds differences in clinical signs and survival rates.

«The TAILOR study draws out attention to the fact that outcomes are poor in second - line treatment of non — small - cell lung cancer, with our available treatments resulting in median progression - free survivals of two or three months,» said Benjamin Solomon, MBBS, PhD, of Peter MacCallum Cancer Centre in Melbcancer, with our available treatments resulting in median progression - free survivals of two or three months,» said Benjamin Solomon, MBBS, PhD, of Peter MacCallum Cancer Centre in MelbCancer Centre in Melbourne.

In several studies, supportive marriages have been shown to improve survival rates in people with cancer, including prostate, lung, and colon canceIn several studies, supportive marriages have been shown to improve survival rates in people with cancer, including prostate, lung, and colon cancein people with cancer, including prostate, lung, and colon cancer.

«The genotoxicity of mainstream smoke carcinogens manifests as mutations occurring in key cancer - related genes, i.e., proto - oncogenes or tumor suppressor genes that control crucial cellular functions, e.g., growth and survival, in lung tumors of active smokers.»

If the best oncologist in the world uses the world's best cancer model to plot the probability distribution function of my survival from the lung cancer he has just diagnosed, and I get hit my a bus on the way home from the appointment, is the model wrong?

The study authors noted that the improved survival rates may come from changes in the management of advanced lung cancer over the past two decades, including new chemotherapy agents and regimens, increased use of salvage chemotherapy and the introduction of molecularly targeted therapies.